MKI67 and breast carcinoma: Currently, the systemic individualized treatment of breast cancer is guided by molecular subtype, which was defined according to the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67.